BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6952962)

  • 1. Phase II study of 4'-epi-doxorubicin in metastatic renal cancer.
    Fosså SD; Wik B; Bae E; Lien HH
    Cancer Treat Rep; 1982 May; 66(5):1219-21. PubMed ID: 6952962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cooperative phase II study of epirubicin (EPI) in bladder cancer, renal pelvic and ureteral tumors--Urological Cooperative Study Group of EPI].
    Niijima T; Koyanagi T; Maru A; Sakashita S; Koiso K; Ishikawa H; Uchida K; Shimazaki J; Isaka S; Akaza H
    Hinyokika Kiyo; 1986 Sep; 32(9):1359-69. PubMed ID: 3468792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A phase I study of 4'-epi-adriamycin, a new anthracycline anticancer agent].
    Kimura K; Wakui A; Saito T; Tominaga T; Niitani H; Fujimoto T; Masaoka T; Toki H; Tamura K
    Gan To Kagaku Ryoho; 1984 Nov; 11(11):2414-9. PubMed ID: 6594078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of 4'-epi-doxorubicin in metastatic melanoma.
    Torti FM; Porzig KJ; Gandara DR; Volberding P; Mitchell E; Meyers FJ; Kohler M; Gribble M
    Cancer Treat Rep; 1984 Dec; 68(12):1509-10. PubMed ID: 6595059
    [No Abstract]   [Full Text] [Related]  

  • 6. [A phase II study of epirubicin in malignant lymphoma].
    Masaoka T; Shibata H; Sampi K; Hirota Y; Yoshida Y; Chiba Y; Shirakawa S; Kobayashi T; Toki H; Tamura K
    Gan To Kagaku Ryoho; 1986 Aug; 13(8):2606-11. PubMed ID: 3461747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of 4'-epi-doxorubicin in patients with advanced malignant melanoma.
    Berman E; Casper ES; Howard J; Wittes RE
    Cancer Treat Rep; 1984 Apr; 68(4):679-80. PubMed ID: 6585272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase of I trial of 4'-epi-Adriamycin.
    Schauer PK; Wittes RE; Gralla RJ; Casper ES; Young CW
    Cancer Clin Trials; 1981; 4(4):433-7. PubMed ID: 7318126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II evaluation of 4'-epi-doxorubicin in patients with metastatic colorectal carcinoma.
    Ajani JA; Kanojia MD; Bodey GP
    Cancer Treat Rep; 1984 Dec; 68(12):1507-8. PubMed ID: 6595058
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II trial of 4'epi-adriamycin for advanced hypernephroma.
    Benedetto P; Ahmed T; Needles B; Watson RC; Yagoda A
    Am J Clin Oncol; 1983 Oct; 6(5):553-4. PubMed ID: 6577784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
    Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
    Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
    Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
    Catimel G; Spielmann M; Dieras V; Kayitalire L; Pouillart P; Guastalla JP; Soler-Michel P; Graffand N; Garet F; Dumortier A; Pellae-Cosset B; Chazard M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):24-7. PubMed ID: 8629032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Lisboa BW; Untch M; Kühnle H; Jänicke F; Meerpohl HG; Lindner C; Konecny G; Hecker D; Diergarten K
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S13-6. PubMed ID: 9071334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
    Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of 4'-epi-doxorubicin in advanced colorectal carcinoma: a Northern California Oncology Group study.
    Meyers FJ; Lewis B; Mitchell E; William L; Hannigan JF; Gribble M; Torti FM
    Cancer Treat Rep; 1985 Jan; 69(1):143-4. PubMed ID: 3855385
    [No Abstract]   [Full Text] [Related]  

  • 17. Preliminary echocardiographic and polygraphic evaluation of cardiac toxicity of 4'-epi-doxorubicin.
    Villani F; Comazzi R; Lacaita G; Genitoni V; Guindani A; Martini A
    Int J Clin Pharmacol Ther Toxicol; 1983 Apr; 21(4):203-8. PubMed ID: 6574995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
    Warner E; Hedley D; Andrulis I; Myers R; Trudeau M; Warr D; Pritchard KI; Blackstein M; Goss PE; Franssen E; Roche K; Knight S; Webster S; Fraser RA; Oldfield S; Hill W; Kates R
    Clin Cancer Res; 1998 Jun; 4(6):1451-7. PubMed ID: 9626462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of esorubicin in the treatment of metastatic carcinoma of the kidney: a study of the Northern California Oncology Group.
    Carlson RW; Williams RD; Billingham ME; Kohler M; Torti FM
    Cancer Treat Rep; 1987; 71(7-8):767-8. PubMed ID: 3607787
    [No Abstract]   [Full Text] [Related]  

  • 20. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
    Giordano SH; Booser DJ; Murray JL; Ibrahim NK; Rahman ZU; Valero V; Theriault RL; Rosales MF; Rivera E; Frye D; Ewer M; Ordonez NG; Buzdar AU; Hortobagyi GN
    Clin Cancer Res; 2002 Nov; 8(11):3360-8. PubMed ID: 12429622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.